Clinical Scorecard: Limonin Reduces Pyroptosis and Inflammation in Myocardial Ischemia-Reperfusion Mice by Targeting the Caspase-3/GSDME Pathway

At a Glance

Key Highlights

• Limonin inhibits OGD/R-induced pyroptosis and inflammatory factor release in myocardial cells via the caspase-3/GSDME pathway.
• In vivo, limonin pretreatment improves cardiac function, reduces myocardial damage, inflammation, apoptosis, and fibrosis in I/R mouse models.
• The protective effect of limonin is mechanistically linked to suppression of caspase-3 activation and GSDME cleavage.

Guideline-Based Recommendations

Diagnosis

• Use gene expression profiling (e.g., GSE225105 dataset) to identify differential gene expression in myocardial I/R injury.
• Assess pyroptosis markers including caspase-3 activation and GSDME cleavage in myocardial tissue.

Management

• Consider limonin as a potential therapeutic agent to reduce myocardial I/R injury by targeting pyroptosis pathways.
• Utilize limonin pretreatment to improve cardiac function and reduce inflammation and fibrosis post-I/R injury.

Monitoring & Follow-up

• Monitor cardiac function indicators and myocardial tissue damage following I/R injury and treatment.
• Evaluate levels of inflammatory cytokines and markers of pyroptosis such as caspase-3 and GSDME activation.

Risks

• Excessive activation of caspase-3/GSDME pathway can exacerbate myocardial damage through pyroptosis and inflammation.
• Potential unknown adverse effects of limonin require further investigation before clinical application.

Patient & Prescribing Data

Experimental mouse models of myocardial ischemia-reperfusion injury; human data not yet available.

Limonin shows cardioprotective effects by inhibiting caspase-3/GSDME-mediated pyroptosis and inflammation, suggesting potential for myocardial protection strategies.

Clinical Best Practices

• Investigate caspase-3/GSDME pathway involvement in myocardial I/R injury to identify therapeutic targets.
• Use natural compounds like limonin with anti-inflammatory and anti-pyroptotic properties for myocardial protection.
• Combine in vitro and in vivo models to validate molecular mechanisms and therapeutic efficacy.

References

• Gene Expression Omnibus (GEO) database